Direct-to-Patient Survey Results Summary
Health Care, Innovation, Supply Chain
During the 2022 GCSG US conference in San Antonio, 65 attendees participated in our Direct-to-Patient (DtP) survey. While 2/3rd’s of the respondents represented pharmaceutical companies / sponsors, there is also a strong mix of input from service providers. Over 50% of participants also had experience with DtP. Though a need for technology improvements was noted, our industry’s adoption of patient centric services like DTP continues to boost the growth of decentralized trials.
Related Education Resources.
All ResourcesNavigating Regulatory and QA Challenges in Clinical Supply Management
Topic: Regulatory
Executive Summary
Members
Nat'l Coronavirus Response - Road Map to Reopening
Topics: Health Care, Strategic Planning
Report
Free
Brexit & the future landscape for clinical trial supplies in the UK and Europe
Topics: Pharma Industry, Regulatory, Supply Chain
Position Paper
Free
